Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
152.43
-2.15 (-1.39%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.
The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S
| Country | Denmark |
| Founded | 2006 |
| IPO Date | Jan 28, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,017 |
| CEO | Jan Mikkelsen |
Contact Details
Address: Tuborg Boulevard 12 Hellerup, 2900 Denmark | |
| Phone | 45 70 22 22 44 |
| Website | ascendispharma.com |
Stock Details
| Ticker Symbol | ASND |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001612042 |
| CUSIP Number | 04351P101 |
| ISIN Number | US04351P1012 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board and Executive Director |
| Scott T. Smith | Chief Financial Officer, Executive Vice President and Member of Executive Board |
| Lotte Sonderbjerg | Executive Vice President, Chief Administrative Officer and Member of the Executive Board |
| Michael Wolff Jensen L.L.M. | Executive Vice President, Chief Legal Officer and Member of the Executive Board |
| Mads Bodenhoff | Senior Vice President of Finance and Principal Accounting Officer |
| Timothy J. Lee | Senior Director of Investor Relations |
| Flemming Steen Jensen | Executive Vice President of Product Supply and Quality |
| Dr. Kennett Sprogoe Ph.D. | Executive Vice President and Head of Research and Product Development |
| Dr. Stina Singel M.D., Ph.D. | Executive Vice President and Head of Clinical Development for Oncology |
| Joseph Kelly | Head of U.S. Commercial of Endocrinology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 21, 2025 | 144 | Filing |
| Feb 20, 2025 | 144 | Filing |
| Feb 19, 2025 | 144 | Filing |
| Feb 19, 2025 | 144 | Filing |
| Feb 18, 2025 | 144 | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Feb 12, 2025 | 6-K | Report of foreign issuer |
| Feb 12, 2025 | 6-K | Report of foreign issuer |
| Feb 12, 2025 | 6-K | Report of foreign issuer |